MedTrace Logo

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06974812 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-01-29

No results posted yet for this study

Summary

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

Conditions

  • Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

IBI3014

12 mg/kg D1 IV Q3W

DRUG

IBI3014

6 mg/kg D1 IV Q3W

DRUG

IBI3014

1 mg/kg D1 IV Q3W

DRUG

IBI3014

15 mg/kg D1 IV Q3W

DRUG

IBI3014

9 mg/kg D1 IV Q3W

DRUG

IBI3014

3 mg/kg D1 IV Q3W

DRUG

IBI3014

20 mg/kg D1 IV Q3W

DRUG

IBI3014

18 mg/kg D1 IV Q3W

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-18
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06974812 on ClinicalTrials.gov